Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
EMERYVILLE, Calif., May 02, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 2:50 p.m. EDT
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 1:40 p.m. PDT
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
